VERV
Price
$11.02
Change
-$0.01 (-0.09%)
Updated
Jul 15 closing price
Capitalization
984.22M
22 days until earnings call
XP
Price
$18.22
Change
+$0.26 (+1.45%)
Updated
Jul 15 closing price
Capitalization
14.07B
34 days until earnings call
Interact to see
Advertisement

VERV vs XP

Header iconVERV vs XP Comparison
Open Charts VERV vs XPBanner chart's image
Verve Therapeutics
Price$11.02
Change-$0.01 (-0.09%)
Volume$3.54M
Capitalization984.22M
XP
Price$18.22
Change+$0.26 (+1.45%)
Volume$6.26M
Capitalization14.07B
VERV vs XP Comparison Chart in %
Loading...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VERV vs. XP commentary
Jul 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VERV is a Hold and XP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (VERV: $11.02 vs. XP: $18.22)
Brand notoriety: VERV and XP are both not notable
VERV represents the Biotechnology, while XP is part of the Investment Banks/Brokers industry
Current volume relative to the 65-day Moving Average: VERV: 71% vs. XP: 97%
Market capitalization -- VERV: $984.22M vs. XP: $14.07B
VERV [@Biotechnology] is valued at $984.22M. XP’s [@Investment Banks/Brokers] market capitalization is $14.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The market cap for tickers in the [@Investment Banks/Brokers] industry ranges from $928.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B. The average market capitalization across the [@Investment Banks/Brokers] industry is $12.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VERV’s FA Score shows that 0 FA rating(s) are green whileXP’s FA Score has 0 green FA rating(s).

  • VERV’s FA Score: 0 green, 5 red.
  • XP’s FA Score: 0 green, 5 red.
According to our system of comparison, both VERV and XP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VERV’s TA Score shows that 4 TA indicator(s) are bullish while XP’s TA Score has 4 bullish TA indicator(s).

  • VERV’s TA Score: 4 bullish, 5 bearish.
  • XP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XP is a better buy in the short-term than VERV.

Price Growth

VERV (@Biotechnology) experienced а -0.99% price change this week, while XP (@Investment Banks/Brokers) price change was -5.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.

The average weekly price growth across all stocks in the @Investment Banks/Brokers industry was -0.29%. For the same industry, the average monthly price growth was +13.81%, and the average quarterly price growth was +13.41%.

Reported Earning Dates

VERV is expected to report earnings on Nov 11, 2025.

XP is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+2.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Investment Banks/Brokers (-0.29% weekly)

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XP($14.1B) has a higher market cap than VERV($984M). VERV YTD gains are higher at: 95.390 vs. XP (53.755). XP has higher annual earnings (EBITDA): 4.5B vs. VERV (-201.62M). XP has more cash in the bank: 45.9B vs. VERV (497M). VERV has less debt than XP: VERV (68.6M) vs XP (40.8B). XP has higher revenues than VERV: XP (6.22B) vs VERV (59.6M).
VERVXPVERV / XP
Capitalization984M14.1B7%
EBITDA-201.62M4.5B-4%
Gain YTD95.39053.755177%
P/E RatioN/A17.66-
Revenue59.6M6.22B1%
Total Cash497M45.9B1%
Total Debt68.6M40.8B0%
TECHNICAL ANALYSIS
Technical Analysis
VERVXP
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 19 days ago
86%
Bullish Trend 16 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADGAX24.95N/A
N/A
AB Core Opportunities A
NWKCX82.64N/A
N/A
Nationwide Geneva Small Cap Gr R6
VSQYX17.85N/A
N/A
Invesco MSCI World SRI Index Y
FDKFX15.61N/A
N/A
Fidelity International Discovery K6
MITTX38.06-0.15
-0.39%
MFS Massachusetts Investors Tr A